CBMX news:
CombiMatrix Corporation (Nasdaq:CBMX), a molecular diagnostics company specializing in DNA-based testing services for developmental disorders and cancer diagnostics, today announced that it has entered into a contractual agreement with Galaxy Health Network for coverage of CombiMatrix's diagnostic laboratory services.
Galaxy Health Network, based in Arlington, TX, has a provider base of more than 400,000 directly contracted physicians, 2,700 hospitals and 47,000 ancillary providers. Its member base has currently more than 3.5 million covered lives. These members now have access to CombiMatrix's suite of molecular diagnostic solutions and comprehensive clinical support – specializing in prenatal, miscarriage and pediatric healthcare.
Mark McDonough, President and Chief Executive Officer of CombiMatrix, noted that the partnership with Galaxy is another opportunity for CombiMatrix to broaden its payor geographic reach. "This agreement further expands our reach throughout the country providing much wider access to our entire portfolio of testing services, including our CombiSNP chromosomal microarray test.
"Our partnership with Galaxy allows us to jointly educate physicians in the Galaxy network about the advantages of chromosomal microarray testing," McDonough said. "We believe our services are a vital addition to important health networks like Galaxy and look forward to a significant and growing commercial and clinical relationship."
